O	0	10	Randomized
O	11	16	Phase
O	17	19	II
O	20	25	Study
O	26	28	of
B-intervention	29	33	Talc
O	34	40	Versus
B-intervention	41	53	Iodopovidone
O	54	57	for
O	58	61	the
O	62	72	Prevention
O	73	75	of
B-condition	76	82	Seroma
I-condition	83	92	Formation
O	93	102	Following
O	103	111	Modified
O	112	119	Radical
O	120	130	Mastectomy
O	130	131	.

O	132	135	The
O	136	140	most
O	141	147	common
O	148	160	complication
O	161	170	following
O	171	179	modified
O	180	187	radical
O	188	198	mastectomy
O	199	201	is
O	202	208	seroma
O	209	218	formation
O	218	219	.

O	220	228	Numerous
O	229	239	approaches
O	240	244	have
O	245	249	been
O	250	259	attempted
O	260	262	to
O	263	270	prevent
O	271	275	this
O	276	288	complication
O	288	289	,
O	290	297	ranging
O	298	302	from
O	303	306	the
O	307	310	use
O	311	313	of
O	314	322	chemical
O	323	333	substances
O	334	336	to
O	337	347	mechanical
O	348	353	means
O	353	354	,
O	355	358	and
O	359	363	none
O	364	366	of
O	367	372	these
O	373	377	have
O	378	384	proven
O	385	387	to
O	388	390	be
O	391	403	consistently
O	404	412	reliable
O	412	413	.

O	414	417	The
O	418	421	aim
O	422	424	of
O	425	429	this
O	430	435	study
O	436	439	was
O	440	442	to
O	443	451	evaluate
O	452	455	the
O	456	462	safety
O	463	466	and
O	467	475	efficacy
O	476	478	of
O	479	483	talc
O	484	486	in
O	487	497	preventing
O	498	511	postoperative
O	512	519	seromas
O	520	528	compared
O	529	533	with
O	534	540	iodine
O	541	544	and
O	545	553	standard
O	554	558	care
O	558	559	.

B-eligibility	560	568	Patients
I-eligibility	569	573	with
I-eligibility	574	580	breast
I-eligibility	581	587	cancer
I-eligibility	588	598	undergoing
I-eligibility	599	607	modified
I-eligibility	608	615	radical
I-eligibility	616	626	mastectomy
O	627	631	were
O	632	640	randomly
O	641	649	assigned
O	650	652	to
O	653	656	one
O	657	659	of
O	660	665	three
O	666	671	study
O	672	678	groups
O	678	679	:
B-control	680	687	control
O	687	688	,
O	689	701	subcutaneous
O	702	706	talc
O	706	707	,
O	708	710	or
O	711	717	iodine
O	718	729	application
O	729	730	.

O	731	734	The
O	735	742	primary
O	743	751	endpoint
O	752	755	was
B-outcome-Measure	756	765	frequency
I-outcome-Measure	766	768	of
I-outcome-Measure	769	775	seroma
I-outcome-Measure	776	785	formation
O	785	786	.

O	787	796	Secondary
O	797	805	outcomes
O	806	814	included
B-outcome-Measure	815	820	wound
I-outcome-Measure	821	834	complications
O	835	836	(
O	836	844	surgical
O	845	849	site
O	850	859	infection
O	859	860	,
O	861	865	flap
O	866	874	necrosis
O	874	875	,
O	876	879	and
O	880	885	wound
O	886	896	dehiscence
O	896	897	)
O	897	898	,
B-outcome-Measure	899	908	analgesic
I-outcome-Measure	909	912	use
O	912	913	,
B-outcome-Measure	914	927	postoperative
I-outcome-Measure	928	932	pain
O	932	933	,
B-outcome-Measure	934	939	total
I-outcome-Measure	940	945	drain
I-outcome-Measure	946	953	outputs
O	953	954	,
O	955	958	and
B-outcome-Measure	959	967	drainage
I-outcome-Measure	968	976	duration
O	976	977	.

O	978	980	Of
O	981	984	the
B-total-participants	985	987	86
O	988	996	patients
O	997	1007	randomized
O	1008	1010	in
O	1011	1014	the
O	1015	1020	study
O	1020	1021	,
B-total-participants	1022	1024	80
O	1025	1029	were
O	1030	1038	analyzed
O	1038	1039	.

O	1040	1045	After
O	1046	1053	interim
O	1054	1062	analysis
O	1062	1063	,
O	1064	1067	the
O	1068	1074	iodine
O	1075	1087	intervention
O	1088	1091	was
B-outcome	1092	1104	discontinued
O	1105	1112	because
O	1113	1115	of
O	1116	1125	increased
B-outcome	1126	1133	adverse
I-outcome	1134	1142	outcomes
O	1143	1144	(
B-outcome	1144	1152	drainage
I-outcome	1153	1161	duration
O	1162	1165	and
B-outcome	1166	1171	total
I-outcome	1172	1178	amount
I-outcome	1179	1181	of
I-outcome	1182	1187	fluid
I-outcome	1188	1195	drained
O	1195	1196	)
O	1196	1197	.

O	1198	1202	Talc
O	1203	1209	failed
O	1210	1212	to
O	1213	1224	demonstrate
O	1225	1229	that
O	1230	1233	its
O	1234	1245	application
O	1246	1248	in
O	1249	1261	subcutaneous
O	1262	1268	breast
O	1269	1275	tissue
O	1276	1284	prevents
B-outcome	1285	1291	seroma
I-outcome	1292	1301	formation
O	1302	1303	(
B-iv-bin-percent	1303	1305	19
I-iv-bin-percent	1305	1306	.
I-iv-bin-percent	1306	1307	4
I-iv-bin-percent	1307	1308	%
O	1309	1312	for
O	1313	1317	talc
O	1318	1323	group
O	1324	1326	vs
O	1326	1327	.
B-cv-bin-percent	1328	1330	23
I-cv-bin-percent	1330	1331	.
I-cv-bin-percent	1331	1332	3
I-cv-bin-percent	1332	1333	%
O	1334	1337	for
O	1338	1345	control
O	1346	1351	group
O	1351	1352	;
O	1353	1354	p
O	1355	1356	=
O	1357	1358	0
O	1358	1359	.
O	1359	1361	70
O	1361	1362	)
O	1362	1363	.

O	1364	1371	However
O	1371	1372	,
O	1373	1381	patients
O	1382	1385	who
O	1386	1395	developed
O	1396	1402	seroma
O	1403	1405	in
O	1406	1409	the
O	1410	1414	talc
O	1415	1420	group
O	1421	1424	had
O	1425	1430	fewer
B-outcome	1431	1442	aspirations
I-outcome	1443	1446	per
I-outcome	1447	1454	patient
I-outcome	1455	1461	seroma
O	1462	1465	and
O	1466	1470	less
B-outcome	1471	1477	volume
I-outcome	1478	1485	drained
O	1486	1490	when
O	1491	1499	compared
O	1500	1504	with
O	1505	1508	the
O	1509	1516	control
O	1517	1522	group
O	1523	1524	(
B-iv-cont-mean	1524	1526	88
I-iv-cont-mean	1526	1527	.
I-iv-cont-mean	1527	1528	2
O	1529	1530	±
B-iv-cont-sd	1531	1533	73
O	1534	1536	vs
O	1536	1537	.
B-cv-cont-mean	1538	1541	158
I-cv-cont-mean	1541	1542	.
I-cv-cont-mean	1542	1543	3
O	1544	1545	±
B-cv-cont-sd	1546	1548	90
I-cv-cont-sd	1548	1549	.
I-cv-cont-sd	1549	1550	5
O	1550	1551	;
O	1552	1553	p
O	1554	1555	=
O	1556	1557	0
O	1557	1558	.
O	1558	1560	17
O	1560	1561	)
O	1561	1562	.

O	1563	1575	Subcutaneous
O	1576	1580	talc
O	1581	1592	application
O	1593	1596	was
O	1597	1601	safe
O	1602	1604	in
O	1605	1608	the
O	1609	1614	short
O	1615	1619	term
O	1619	1620	,
O	1621	1624	but
O	1625	1630	there
O	1631	1634	was
O	1635	1638	not
O	1639	1649	sufficient
O	1650	1658	evidence
O	1659	1661	to
O	1662	1669	support
O	1670	1673	its
O	1674	1677	use
O	1678	1681	for
O	1682	1688	seroma
O	1689	1699	prevention
O	1700	1709	following
O	1710	1718	modified
O	1719	1726	radical
O	1727	1737	mastectomy
O	1738	1740	in
O	1741	1749	patients
O	1750	1754	with
O	1755	1761	breast
O	1762	1768	cancer
O	1768	1769	.
